5-fluoro-3-nitropyridin-2-amine

We are 5-fluoro-3-nitropyridin-2-amine CAS:212268-12-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  5-fluoro-3-nitropyridin-2-amine
CAS.NO:212268-12-7
Synonyms:5-fluoro-3-nitropyridine-2-amine;
2-amino-5-fluoro-3-nitropyridine;
5-Fluoro-3-nitro-2-aminopyridine;
2-Amino-3-nitro-5-fluoropyridine;
Molecular Formula:C5H4FN3O2
Molecular Weight:157.10300
 
Physical and Chemical Properties:
Density:1.6±0.1 g/cm3
Melting point:/
Boiling point:290.1±35.0 °C at 760 mmHg
Flash point:129.3±25.9 °C
Index of Refraction:1.612
 
Specification:
Appearance:White Crystalline Powder
Purity:≥99.0%
 
Packing:5 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:  used in the pharmaceutical intermediate

5-fluoro-3-nitropyridin-2-amine


Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Ethyldiisopropylamine CAS:7087-68-5 It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.Bromuro de propionilo CAS:598-22-1 It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.65-46-3 In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
H-LYS-LYS-LYS-OH View Details
Ethyl 2-BOC-aminothiazole-5-carboxylate View Details
(3-dibenzothiophen-4-ylphenyl)boronic acid View Details
2-methoxy-5-((((1S)-1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)ethyl)amino)methyl)benzoic acid manufacturer Bis(Tetramethylene)Fluoroformamidinium Hexafluorophosphate manufacturer tert-Butyl (S)-3-(4-aminophenyl)piperidine-1-carboxylate manufacturer 10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine manufacturer 2-piperazin-1-ylpyrimidine,hydrochloride manufacturer